NRx Pharmaceuticals announced the formation of NRx Defense Systems Inc., a Florida-based research and development subsidiary dedicated to advancing neuroplastic treatments. The subsidiary is focused on combined neuroplastic treatments using D-cycloserine and transcranial magnetic stimulation supported by robotic-enabled neuronavigation.
Leadership and Development
The subsidiary will be led by Dr. Dennis McBride, with support from Chief Medical Innovation Officer Dr. Joshua Brown. NRx Defense Systems aims to pursue non-dilutive government and institutional funding while developing deployable solutions for military and first responder use.
The company is developing a prototype in partnership with Zeta Surgical Inc., expected to be unveiled at the Clinical TMS Society annual meeting in June 2026.
About NRx Pharmaceuticals
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for treating central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. The company is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101 (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for suicidal ideation in depression, including bipolar depression, while NRX-101 has been awarded Breakthrough Therapy Designation for suicidal bipolar depression.
NRx has filed an Abbreviated New Drug Application and initiated a New Drug Application filing for NRX-100 with an application for the Commissioner’s National Priority Voucher Program for treating suicidal ideation in patients with depression, including bipolar depression.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://www.financialcontent.com/article/nnwire-2026-4-15-defensenewsbreaks-nrx-pharmaceuticals-inc-nasdaq-nrxp-forms-nrx-defense-systems-subsidiary-to-advance-neuroplastic-therapies-for-military-and-government-applications